Golidocitinib with immunotherapy for extensive-stage small cell lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of golidocitinib (a targeted pill) and a PD-1 inhibitor (a type of immunotherapy) as a maintenance treatment after initial chemotherapy. It may help keep your lung cancer from growing longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have extensive-stage small cell lung cancer that hasn't been treated before.
- You are 18 or older and in generally good health (able to do daily activities).
- You have at least one tumor that can be measured on a scan.
- Your kidney, liver, and blood counts are within normal ranges.
- You are willing to use effective birth control during and for 6 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two immunotherapy drugs (ivonescimab and cadonilimab) plus chemotherapy for people with extensive-stage small cell lung cancer. It's for those who either haven't been treated before or have had only one prior treatment that included a PD-1/PD-L1 drug and it worked for a while.
This trial tests a combination of two drugs—golidocitinib (a targeted pill) and sintilimab (an immunotherapy)—for people with advanced non-small cell lung cancer that has a high PD-L1 protein level. It may offer a new option if you haven't had immunotherapy before.
This trial tests a combination of golidocitinib (a targeted pill) and an immunotherapy drug (anti-PD-1) for people with non-small cell lung cancer that has come back or spread after prior treatment. It aims to see if this new combination can shrink tumors or stop them from growing.
This trial tests if taking golidocitinib pills after first treatment helps keep peripheral T-cell lymphoma from coming back. You'll either get the study drug or a placebo (no active drug), and your doctor will watch how you do.
This trial looks at whether adding a targeted therapy called anlotinib to immunotherapy maintenance can help people with extensive-stage small cell lung cancer who have already completed 4-6 cycles of standard chemoimmunotherapy without the cancer getting worse.
This trial tests a drug called golidocitinib for people with advanced lung cancer who developed serious, hard-to-treat blood-related side effects (like low white blood cells, low platelets, or anemia) from immunotherapy. The goal is to see if golidocitinib can help reverse these side effects without stopping cancer treatment.
Hear when a new SCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.